Veeco and Leica Microsystems Announce Life Science Collaboration
News Apr 18, 2007
Veeco Instruments Inc. and Leica Microsystems GmbH have finalized a collaboration to drive research in biological and nano-medicine communities. The initial phase of the collaboration focuses on the integration of Veeco’s BioScope™ II atomic force microscope (AFM) with Leica’s DMI series of inverted microscopes.
The alliance will yield high-resolution images for cell biology, enabling researchers to uncover positive ways to impact human disease and treatment. Veeco and Leica Microsystems will debut their collaboration at the AFM BioMed conference in Barcelona, Spain, April 19-21 with a common marketing campaign.
“Veeco’s work with Leica Microsystems provides a powerful opportunity to move the bioscience community forward,” commented Francis Steenbeke, Vice President, Life Science, for Veeco.
“Now researchers from all specialties can integrate AFM technology with optical fluorescence and confocal microscopy. This first step will greatly improve the future of research in the bioscience community. This collaboration with Leica Microsystems is the latest in a series of actions Veeco is taking to expand our commitment to the life science research community, which has included strengthening our life science engineering and applications support and partnering with global life science industry experts who can help guide us in our product development process,” Steenbeke continued.
The design of the BioScope II enables in-situ techniques for measuring biological samples in three dimensions and, when integrated with Leica’s DMI series of inverted optical or, at a later step, confocal microscopes, will give the live cell researcher an intelligent, fully-automated and coded instrument.
“With its leading technologies in high resolution confocal microscopy and its broad range of applicationdriven solutions in fluorescence light microscopy, Leica Microsystems provides an excellent basis for further expansions and combinations of optical microscopy and AFM technologies,” added Martin Haase, General Manager of Leica’s Life Science Research Division. “This kind of collaboration underlines Leica’s strategy to further extend its innovative product offering by open innovation projects.”
Together, the pair is ideal for a wide array of bioscience applications, such as spatial identification of protein molecules and cellular structures, investigations of cell response to mechanical stimulation and nano-manipulation, and in-situ pharmacological studies of live cells.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.